InflaRx (IFRX) Non-Current Assets (2016 - 2026)
InflaRx's (IFRX) quarterly Non-Current Assets came in at $1.8 million in Q2 2026, down 78.65% year-over-year from $8.2 million in Q2 2025, and up 0.58% quarter-over-quarter from $1.7 million in Q1 2026.
Analysis
InflaRx (IFRX) Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has disclosed Non-Current Assets across 11 years of filings, most recently posting $1.8 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 78.65% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $7.3 million (down 65.16% YoY), while the FY2025 annual figure was $1.8 million, down 61.66% from the prior year.
- Non-Current Assets came in at $1.8 million for Q2 2026 at InflaRx, up from $1.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $22.6 million in Q2 2023 to a low of $1.5 million in Q1 2025.
- Average Non-Current Assets over 5 years is $5.8 million, with a median of $3.6 million recorded in 2022.
- Year-over-year, Non-Current Assets tumbled 93.0% in 2022 and soared 745.61% in 2023.
- Over 5 years, Non-Current Assets stood at $5.1 million in 2022, then jumped by 127.04% to $11.6 million in 2023, then sank by 59.66% to $4.7 million in 2024, then slumped by 60.5% to $1.8 million in 2025, then dropped by 4.57% to $1.8 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $1.8 million in Q2 2026, $1.7 million in Q1 2026, and $1.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 1.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Mar 31, 2026 | 1.75 Mn |
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 4.48 Mn |
| Dec 31, 2023 | 11.56 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 22.59 Mn |
| Mar 31, 2023 | 10.63 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 2.40 Mn |
| Jun 30, 2022 | 2.67 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 33.70 Mn |
| Sep 30, 2021 | 34.34 Mn |